| pubmed-article:8302307 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8302307 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8302307 | lifeskim:mentions | umls-concept:C1711254 | lld:lifeskim |
| pubmed-article:8302307 | lifeskim:mentions | umls-concept:C0036579 | lld:lifeskim |
| pubmed-article:8302307 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8302307 | lifeskim:mentions | umls-concept:C1515568 | lld:lifeskim |
| pubmed-article:8302307 | pubmed:dateCreated | 1994-3-9 | lld:pubmed |
| pubmed-article:8302307 | pubmed:abstractText | Selegiline (L-deprenyl) has been recommended as an antiparkinsonian drug to be used as an adjunct to therapy with L-dopa, if and when L-dopa starts to lose its effect. However, initial selegiline monotherapy followed by L-dopa may be both effective and safe. A double-blind, placebo-controlled trial was carried out in previously untreated patients with Parkinson's disease randomized to receive selegiline (10 mg/day; 27 patients) or placebo (25 patients) until L-dopa treatment became imperative. Three rating scales were used for assessment. The study design continues to be double-blind even after L-dopa is introduced. L-Dopa was needed after 545 +/- 90 days in the selegiline group. This was significantly later (p = 0.03) than after placebo (372 +/- 28 days). Disability was less severe in the selegiline group, and there were no serious adverse effects. A nearly twofold dose of L-dopa was needed in the placebo group to achieve a sufficient therapeutic effect during long-term treatment. These results show that selegiline is safe and effective as monotherapy in early parkinsonism. It delays the need for L-dopa treatment and reduces the amount of daily L-dopa required. This could be explained by either a symptomatic effect or neuroprotective efficacy or, more likely, a combination of both. | lld:pubmed |
| pubmed-article:8302307 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8302307 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8302307 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8302307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8302307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8302307 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8302307 | pubmed:issn | 0885-3185 | lld:pubmed |
| pubmed-article:8302307 | pubmed:author | pubmed-author:MyllyläV VVV | lld:pubmed |
| pubmed-article:8302307 | pubmed:author | pubmed-author:SotaniemiK... | lld:pubmed |
| pubmed-article:8302307 | pubmed:author | pubmed-author:HeinonenE HEH | lld:pubmed |
| pubmed-article:8302307 | pubmed:author | pubmed-author:VuorinenJ AJA | lld:pubmed |
| pubmed-article:8302307 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8302307 | pubmed:volume | 8 Suppl 1 | lld:pubmed |
| pubmed-article:8302307 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8302307 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8302307 | pubmed:pagination | S41-4 | lld:pubmed |
| pubmed-article:8302307 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:meshHeading | pubmed-meshheading:8302307-... | lld:pubmed |
| pubmed-article:8302307 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8302307 | pubmed:articleTitle | Selegiline in de novo parkinsonian patients: the Finnish study. | lld:pubmed |
| pubmed-article:8302307 | pubmed:affiliation | Department of Neurology, University of Oulu, Finland. | lld:pubmed |
| pubmed-article:8302307 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8302307 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8302307 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8302307 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8302307 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8302307 | lld:pubmed |
